Deoxycholic acid - Kythera Biopharmaceuticals

Drug Profile

Deoxycholic acid - Kythera Biopharmaceuticals

Alternative Names: ATX-101-Kythera; Belkyra; Kybella; Sodium deoxycholate; Sodium desoxycholate

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kythera Biopharmaceuticals
  • Developer Bayer Dermatology; Kythera Biopharmaceuticals
  • Class Choleretics; Cholic acids; Gallstone therapies; Small molecules
  • Mechanism of Action Cell membrane modulators; Membrane lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Subcutaneous fat disorders
  • No development reported Lipoma

Most Recent Events

  • 13 Oct 2016 Registered for Subcutaneous fat disorders in Norway, Bulgaria, Romania, Latvia, Estonia, Lithuania, Austria, Hungary, Iceland, Sweden (SC)
  • 01 Aug 2016 Kythera Biopharmaceuticals completes a phase III trial for Subcutaneous fat disorders in Canada and USA (NCT02163902)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lipoma in USA (Intralesional, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top